

(21) Application No:	1516997.2	(51) INT CL:	A61K 9/00 (2006.01)A61K 9/14 (2006.01) A61K 9/50 (2006.01)A61K 31/4422 (2006.01) A61P 9/00 (2006.01)
(22) Date of Filing:	11.03.2014	(56) Documents Cited:	US 20120321597 A1US 20120164226 A1 US 20110201685 A1US 20100185219 A1 US 20100113318 A1US 20080317855 A1
Date Lodged:	25.09.2015	(58) Field of Search:	INT CL A61K, C07D Other: PatBase (PGPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD), FreePatentsOnline (US Pat, PgPub, EPO, JPO, WIPO, NPL), Google Scholar (PL, NPL)
(30) Priority Data:			
(31) 13793767	(32) 11.03.2013	(33) US	
(86) International Application Data:	PCT/US2014/023748 En 11.03.2014		
(87) International Publication Data:	WO2014/164904 En 09.10.2014		
(71) Applicant(s):	Edge Therapeutics, Inc. 200 Connell Drive Berkeley Heights, NJ 07922, United States of America		
(72) Inventor(s):	Loch R MacDonald		
(74) Agent and/or Address for Service:	J A Kemp 14 South Square, Gray's Inn, LONDON, WC1R 5JJ, United Kingdom		

- (54) Title of the Invention: **Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage**
Abstract Title: **Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage**
- (57) The described invention provides a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury using a flowable sustained release particulate composition.




FIGURE 1